NCT00625755View on ClinicalTrials.gov

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

February 29, 2008

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

Electrofusion DC vaccine

To assess the safety and efficacy of vaccinations

Trial Locations (1)

02215

BIDMC, Boston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00625755 - A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter